Skip to main content

Table 2 Demographics of dogs enrolled in the survey and prevention studies

From: Field safety and efficacy of an orally administered combination of sarolaner, moxidectin and pyrantel (Simparica Trio®) for the prevention of angiostrongylosis in dogs presented as veterinary patients

Signalment Survey study Prevention study
All dogs
(n = 1623)
A. vasorum positive
(n = 198)
Placebo
(n = 307)
Simparica Trio®a
(n = 315)
Purebred (%) 1153 (71.0) 125 (63.1) 240 (78.2) 237 (75.2)
Non-purebred (%) 470 (29.0) 73 (36.9) 67 (21.8) 78 (24.8)
Age mean (years) 5.1 3.8 4.5 4.2
Age range (years) 0.1–16.0 0.1–14.0 0.2–15.0 0.2–13.0
Body weight mean (kg) nd nd 21.6 21.0
Body weight range (kg) nd nd 2.5–47.6 2.0–54.4
Male (%) 806 (49.7) 110 (55.6) 148 (48.2) 144 (45.7)
Female (%) 817 (50.3) 88 (44.4) 159 (51.8) 171 (54.3)
Lives mostly indoors (%) 106 (6.5) 8 (4.0) 10 (3.3) 11 (3.5)
Lives mostly outdoors (%) 609 (37.5) 106 (53.5) 120 (39.1) 125 (39.7)
Lives indoors and outdoors (%) 908 (55.9) 84 (42.4) 177 (57.7) 179 (56.8)
  1. aSimparica Trio® provided 1.2 to 2.4 mg/kg sarolaner, 24 to 48 µg/kg moxidectin and 5 to 10 mg/kg pyrantel (as pamoate salt) oral doses per kg body weight
  2. Abbreviation: nd, not determined